Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells

Abstract The development of acquired EGFR‐TKI therapeutic resistance is still a serious clinical problem in the management of lung adenocarcinoma. Peroxisome proliferator activated receptor gamma (PPARγ) agonists may exhibit anti‐tumor activity by transactivating genes which are closely associated w...

Full description

Bibliographic Details
Main Authors: Jie Ni, Lei‐lei Zhou, Li Ding, Xue‐qin Zhang, Xia Zhao, Huizi Li, Haixia Cao, Siwen Liu, Zhuo Wang, Rong Ma, Jianzhong Wu, Jifeng Feng
Format: Article
Language:English
Published: Wiley 2018-05-01
Series:Cancer Medicine
Subjects:
Efatutazone
gefitinib‐resistance
lung adenocarcinoma
peroxisome proliferator‐activated receptor gamma
T0901317
Online Access:https://doi.org/10.1002/cam4.1440

Internet

https://doi.org/10.1002/cam4.1440

Similar Items